Boehringer injects €230 million in new Biologicals Development Center

pharmafile | June 26, 2018 | News story | Manufacturing and Production Boehringer Ingelheim, biologics, manufacturing, pharma 

Prominent industry player Boehringer Ingelheim has unveiled plans to invest €230 million into the construction of a new Biologicals Development Center in Germany.

The investment is a bid to expand developmental capacity in order to facilitate growth in the company’s drug pipeline, which will in turn free up resources for contract manufacturing. The new site will focus development in areas of unmet medical need, featuring a combination of biologics analytical and process development, as well as manufacturing capacity for clinical studies.  

The new facility will be located alongside its existing Research and Development site in Biberach. It is expected to launch in staggered phases beginning in 2020 and will employ 500 staff. The company also has existing biopharmaceutical facilities in Austria, China, and the US.

“The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” commented Dr Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached 40%.”

Matt Fellows

Related Content

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) …

Astellas plans to invest over €330m in new facility in Ireland

Astellas Pharma has announced that it is preparing to submit a planning application to build …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Latest content